Should I buy or sell Bone Biologics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bone Biologics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BBLG shares. View BBLG analyst ratings or view top-rated stocks .

What is Bone Biologics' stock price target for 2024?

1 analysts have issued 1 year target prices for Bone Biologics' stock. Their BBLG share price targets range from $67.50 to $67.50. On average, they expect the company's stock price to reach $67.50 in the next twelve months. This suggests a possible upside of 15,895.3% from the stock's current price. View analysts price targets for BBLG or view top-rated stocks among Wall Street analysts .

How have BBLG shares performed in 2023?

Bone Biologics' stock was trading at $6.2910 at the beginning of 2023. Since then, BBLG shares have decreased by 93.3% and is now trading at $0.4220. View the best growth stocks for 2023 here .

When did Bone Biologics' stock split?

Bone Biologics shares reverse split before market open on Wednesday, June 7th 2023. The 1-30 reverse split was announced on Wednesday, June 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Bone Biologics?

Shares of BBLG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Bone Biologics Stock Price, News & Analysis (OTC:BBLG)

$0.41

-0.01 (-2.13%)

(As of 04:30 PM ET)

Compare

Today's Range: $0.40
▼
$0.43
50-Day Range: $0.42
▼
$0.78
52-Week Range: $0.40
▼
$13.20

Volume: 158,308 shs
Average Volume: 369,659 shs
Market Capitalization: $1.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $67.50

Stock Analysis Analyst Forecasts Chart Headlines Ownership

Bone Biologics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 15,895.3% Upside
$67.50 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($8.15) to ($10.63) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.54 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Bone Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $67.50, Bone Biologics has a forecasted upside of 15,895.3% from its current price of $0.42.
Amount of Analyst Coverage
Bone Biologics has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for BBLG.

0.0

Dividend Strength

Dividend Yield
Bone Biologics does not currently pay a dividend.
Dividend Growth
Bone Biologics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BBLG.

0.6

News and Social Media Coverage

Search Interest
8 people have searched for BBLG on MarketBeat in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bone Biologics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.90% of the stock of Bone Biologics is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Bone Biologics are expected to decrease in the coming year, from ($8.15) to ($10.63) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bone Biologics is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bone Biologics is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Bone Biologics has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Bone Biologics Stock (OTC:BBLG)

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

BBLG Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BBLG Stock News Headlines

November 20, 2023 | msn.com

Why Bone Biologics Stock (BBLG) Is Falling Sharply

November 20, 2023 | finance.yahoo.com

Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 17, 2023 | msn.com

Why Bone Biologics Stock (BBLG) Is Getting Obliterated Friday

November 16, 2023 | finance.yahoo.com

Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

November 15, 2023 | finance.yahoo.com

BBLG Offers Good Entry Opportunity

November 14, 2023 | msn.com

What Are Biologics?

November 14, 2023 | morningstar.com

Bone Biologics Corp BBLG

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

September 26, 2023 | finance.yahoo.com

Bone Biologics Provides Scientific Update on NB1 Bone Graft Device

September 24, 2023 | abcnews.go.com

Robin Roberts' sister reflects on sibling's upcoming wedding after lifesaving bone marrow donation

September 22, 2023 | bbc.co.uk

Bone broth

September 15, 2023 | finance.yahoo.com

Insider Buying: CFO Deina Walsh Acquires 8,000 Shares of Bone Biologics Corp (BBLG)

September 13, 2023 | finance.yahoo.com

CEO Jeff Frelick Buys 9,500 Shares of Bone Biologics Corp (BBLG)

August 23, 2023 | nypost.com

Man killed roommate, and lived with body in closet for months

August 17, 2023 | detroitnews.com

TB death in Michigan linked to contaminated bone graft material

August 15, 2023 | finance.yahoo.com

BBLG Advances Crucial Technology and Solidifies Funding

August 4, 2023 | msn.com

Second deadly TB outbreak linked to tainted bone grafts

July 31, 2023 | msn.com

Deadly tuberculosis outbreaks in US linked to tainted bone grafts

July 6, 2023 | msn.com

Bone Biologics (BBLG) Price Target Increased by 738.89% to 38.51

June 22, 2023 | marketwatch.com

BioMedNewsBreaks - Bone Biologics Corporation (NASDAQ: BBLG) Announces $5M Underwritten Public Offering

June 16, 2023 | msn.com

Bone Biologics stock plummets more than 50% after stock offering prices at deep discount

June 15, 2023 | msn.com

Bone Biologics slumps 50%, prices $5M offering

June 15, 2023 | msn.com

Bone Biologics Nosedives on $5M Stock Offering

June 15, 2023 | finance.yahoo.com

Bone Biologics Prices $5.0 Million Underwritten Public Offering

June 8, 2023 | finance.yahoo.com

BBLG - Bone Biologics Corporation

June 8, 2023 | finance.yahoo.com

BBLG: BBLG Advances Crucial Technology and Solidifies Funding

See More Headlines

Receive BBLG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bone Biologics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 11/29/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTC
Industry: Medical Devices
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTC:BBLG
CUSIP: N/A
CIK: N/A
Web: www.bonebiologics.com
Phone: 781-552-4452
Fax: N/A
Employees: 2
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $67.50
High Stock Price Target: $67.50
Low Stock Price Target: $67.50
Potential Upside/Downside: +15,895.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.21)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-1,490,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -123.44%
Return on Assets: -82.64%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.95
Quick Ratio: 3.95

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.82 per share
Price / Book: 0.23

Miscellaneous

Outstanding Shares: 3,134,000
Free Float: 2,886,000
Market Cap: $1.32 million
Optionable: Not Optionable
Beta: 0.08

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Jeffrey Frelick (Age 57)
CEO & President
Comp: $337.75k
Ms. Deina H. Walsh (Age 59)
Chief Financial Officer
Comp: $218.88k
Dr. Shun'ichi Kuroda
Co-Founder & Member of Scientific Advisory Board

Key Competitors

View All Competitors

BBLG Stock Analysis - Frequently Asked Questions

Should I buy or sell Bone Biologics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bone Biologics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BBLG shares.
View BBLG analyst ratings or view top-rated stocks.
What is Bone Biologics' stock price target for 2024?: 1 analysts have issued 1 year target prices for Bone Biologics' stock. Their BBLG share price targets range from $67.50 to $67.50. On average, they expect the company's stock price to reach $67.50 in the next twelve months. This suggests a possible upside of 15,895.3% from the stock's current price.
View analysts price targets for BBLG or view top-rated stocks among Wall Street analysts.
How have BBLG shares performed in 2023?: Bone Biologics' stock was trading at $6.2910 at the beginning of 2023. Since then, BBLG shares have decreased by 93.3% and is now trading at $0.4220.
View the best growth stocks for 2023 here.

When did Bone Biologics' stock split?: Bone Biologics shares reverse split before market open on Wednesday, June 7th 2023. The 1-30 reverse split was announced on Wednesday, June 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
How do I buy shares of Bone Biologics?: Shares of BBLG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTC:BBLG) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Bone Biologics Stock Price, News & Analysis (OTC:BBLG)

Bone Biologics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

Company Ownership

Earnings and Valuation

About Bone Biologics Stock (OTC:BBLG)

BBLG Stock Price History

BBLG Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

BBLG Stock Analysis - Frequently Asked Questions

Overall MarketRank^™